Has HER2+ First-Line Treatment Officially Changed? – Dr. Neil Iyengar & Dr. Martin Dietrich

Recorded at SABCS 2025, Dr. Neil Iyengar and Dr. Martin Dietrich break down the data that may finally dethrone CLEOPATRA as the long-standing first-line standard for HER2-positive metastatic breast cancer.

From the historic success of dual HER2 inhibition to the game-changing DESTINY-Breast09 results showing median PFS exceeding 40 months, this conversation explores what true progress looks like — and how it should change clinical practice.

They dive into brain metastases risk, durability of response, toxicity management, patient selection, and why using the most effective therapy first may no longer be optional.

🎧 A must-watch discussion on evidence-based change in the HER2+ treatment landscape.